StockData
CorMedix Inc. logo

CorMedix Inc. (CRMD) stock

CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$4.67−0.15 (-3.11%)

Close on Nov 17, 2026Market cap $364.00MP/E –Yield –

Earnings

CorMedix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$101.90M
+156.7% on a year earlier
EPS, Q2 FY2026
$0.29
$0.28 a year earlier
Latest guidance
Issued
Nov 2, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of CorMedix's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open$101.90M+156.7%$0.29Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open$127.40M+226.7%$0.43Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026before the open$128.60M+312.2%$0.16Release
Q3 FY2025ended Sep 30, 2025Oct 20, 2025before the open$100.00M+769.6%–Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$39.70M+4862.5%$0.28Release
Q1 FY2025ended Mar 31, 2025Apr 8, 2025before the open$39.00M––Release
Q4 FY2024ended Dec 31, 2024Mar 25, 2025before the open$31.20M–$0.22Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$11.50M–-$0.05Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024before the open$800.00K–-$0.25Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open––-$0.25Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

CorMedix's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
consolidated revenueFY2026$325.00M – $345.00M$325.00M – $345.00MReaffirmedAug 13, 2026
net revenueGAAPFY2026$300.00M – $320.00M–NewMar 5, 2026
total revenueFY2026$325.00M – $345.00M–NewNov 2, 2026
adjusted EBITDAnon-GAAPFY2026$125.00M – $140.00M$115.00M – $135.00MRaisedAug 13, 2026
adjusted EBITDAnon-GAAPFY2026$100.00M – $125.00M–NewMar 5, 2026
Cash OpExFY2026$145.00M – $155.00M–RaisedAug 13, 2026
operating expenses, excluding non-cash items and one-time expensesnon-GAAPFY2026$145.00M – $160.00M–NewJan 8, 2026
targeted synergiesFY2026$5.00M – $15.00M–NewOct 20, 2025
DefenCath salesFY2027$100.00M – $140.00M–NewJan 8, 2026

Guidance vs results

The last range CorMedix gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$375.00M$307.30MΣ4QBelow range

Guidance history

Every forecast CorMedix put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2026total revenueFY2026$325.00M – $345.00MNew
Aug 13, 2026adjusted EBITDAFY2026$125.00M – $140.00MRaised
Aug 13, 2026Cash OpExFY2026$145.00M – $155.00MRaised
Aug 13, 2026consolidated revenueFY2026$325.00M – $345.00MReaffirmed
May 14, 2026adjusted EBITDAFY2026$115.00M – $135.00MRaised
May 14, 2026net revenueFY2026$325.00M – $345.00MRaised
Mar 5, 2026adjusted EBITDAFY2026$100.00M – $125.00MNew
Mar 5, 2026net revenueFY2026$300.00M – $320.00MNew
Jan 8, 2026Adjusted EBITDAFY2026$100.00M – $125.00MNew
Jan 8, 2026operating expenses, excluding non-cash items and one-time expensesFY2026$145.00M – $160.00MNew
Jan 8, 2026RevenueFY2026$300.00M – $320.00MNew
Jan 8, 2026DefenCath revenueFY2026$150.00M – $170.00MLowered
Jan 8, 2026DefenCath salesFY2027$100.00M – $140.00MNew
Oct 20, 2025year end cash and cash equivalent balanceFY2025$100.00MNew
Oct 20, 2025cost synergy captureQ4 FY2025$30.00MNew
Oct 20, 2025targeted synergiesFY2026$5.00M – $15.00MNew
Oct 20, 2025pro forma net revenueFY2025$375.00MNew
Apr 8, 2025Net Sales to existing purchasing customersFY2025$62.00M – $70.00MRaised
Mar 25, 2025cash operating expenseFY2025$72.00M – $78.00MNew
Mar 25, 2025net revenueFY2025$50.00M – $60.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases CorMedix filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Results
  6. Update
  7. Results
  8. News
  9. News
  10. Update
  11. Results
  12. Update
  13. Update
  14. Results
  15. Results

See a number that looks wrong?